Literature DB >> 16123221

Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.

Stefan Faderl1, Kim-Anh Do, Marcella M Johnson, Michael Keating, Susan O'brien, Iman Jilani, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Christine Aguilar, Amanda Dey, Deborah A Thomas, Francis J Giles, Hagop M Kantarjian, Maher Albitar.   

Abstract

Angiogenesis plays an important role in solid tumors and hematologic malignancies. The prognostic significance of angiogenic factors in adult acute lymphoblastic leukemia (ALL) remains ambiguous. We therefore analyzed the impact of angiogenic factor levels on overall survival of newly diagnosed adult ALL patients. Plasma levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-1 receptor alpha (IL-1Ralpha), IL-6, IL-8, VEGF receptors VEGFR1 and VEGFR2, and thrombopoietin (TPO) were measured in plasma samples of 95 patients by enzyme-linked immunosorbent assay (ELISA). In a univariate Cox proportional hazards model, higher levels of IL-1Ralpha, IL-8, VEGFR1, and VEGFR2 were predictive of poor survival. In contrast, higher levels of VEGF were predictive of longer survival, and higher levels of bFGF suggested a similar trend (P = .09). The multivariate model simultaneously included VEGF (relative risk [RR] for death, 8.01; P = .001 for levels less than or equal to 19.5 pg/mL), IL-1Ralpha (RR, 5.12; P = .007 for levels greater than 373 pg/mL), and VEGFR2 (RR, 4.01; P = .04 for levels greater than 8222 pg/mL) as independent factors for survival. Of interest is the association of high levels of VEGF with good prognosis and higher levels of VEGF receptors with poor outcome. These data reflect the complexity by which angiogenic factors may affect the clinical behavior of patients with ALL, and this complexity should be considered in any therapeutic strategy incorporating antiangiogenic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123221     DOI: 10.1182/blood-2005-03-1010

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  Effect of heat shock protein-90 (HSP90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: an immunohistochemical study.

Authors:  Abdullah Hacıhanefioglu; Emel Gonullu; Ozgur Mehtap; Hakan Keski; Melike Yavuz; Cengiz Ercin
Journal:  Med Oncol       Date:  2010-04-27       Impact factor: 3.064

3.  Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections.

Authors:  Sasisekhar Bennuru; Grace Maldarelli; V Kumaraswami; Amy D Klion; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

4.  Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments.

Authors:  Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Zeynep Alpay Savasan; Shali Mazaki-Tovi; Sun Kwon Kim; Edi Vaisbuch; Adi L Tarca; Pooja Mittal; Giovanna Ogge; Ichchha Madan; Zhong Dong; Lami Yeo; Sonia S Hassan; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2010-09

5.  A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Adi L Tarca; Juan Pedro Kusanovic; Francesca Gotsch; Pooja Mittal; Sun Kwon Kim; Edi Vaisbuch; Shali Mazaki-Tovi; Offer Erez; Zhong Dong; Chong Jai Kim; Lami Yeo; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2010-06       Impact factor: 8.661

6.  Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia.

Authors:  Richa Tripathi; Gayatri Rath; Ranju Ralhan; Sunita Saxena; Sudha Salhan
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

7.  A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.

Authors:  Mark P Purdue; Jonathan N Hofmann; Troy J Kemp; Anil K Chaturvedi; Qing Lan; Ju-Hyun Park; Ruth M Pfeiffer; Allan Hildesheim; Ligia A Pinto; Nathaniel Rothman
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113

Review 8.  Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

Authors:  Keith J August; Aru Narendran; Kathleen A Neville
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

9.  What role for angiogenesis in childhood acute lymphoblastic leukaemia?

Authors:  P Schneider; I Dubus; F Gouel; E Legrand; J P Vannier; M Vasse
Journal:  Adv Hematol       Date:  2011-11-09

10.  Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia.

Authors:  Chuhl Joo Lyu; Sun Young Rha; Sung Chul Won
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.